Carvacrol enhances the sensitıvity of cetuximab in lung cancer cells through inducing apoptosis and cell cycle arrest
Yükleniyor...
Dosyalar
Tarih
2025
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bangladesh Pharmacological Soc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
The intention of this work was to analyze that carvacrol could enhance cancer-inhibiting potency of cetuximab (monoclonal antibody) in lung cancer cells. The combination of cetuximab and carvacrol was found to co-operatively suppress cell proliferation by enhancing apoptosis and inducing cell cycle arrest in A-549 and H1299 cells. Furthermore, the combination therapy triggered cell death by inducing membrane disruption. The most effective combinations were IC10 cetuximab + IC10 carvacrol for A-549 and IC20 cetuximab + IC10 carvacrol for H1299 (CI = 2.0). LDH activity increased by 101% in A-549 and 239% in H1299 (p<0.05). Caspase-3 activity rose by 1.6-fold in A549 and 1.4-fold in H1299 (p<0.05). The combination decreased PCNA, topoisomerase II-alpha, and cyclins D1, D2, E, A, and B (p<0.05). Overall, the combination of carvacrol and cetuximab appears to enhance anti-cancer efficacy and may significantly improve therapeutic outcomes in lung cancer cells.
Açıklama
Anahtar Kelimeler
Growth-Factor Receptor, Monoclonal-Antibody, Neck-Cancer, Chemical-Composition, Essential Oils, Egfr, Expression, Antioxidant, Chemotherapy, Inhibition
Kaynak
Bangladesh Journal of Pharmacology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
20
Sayı
1
